文献速递系统性红斑狼疮

狼疮性肾炎治疗:从序贯到联合与个体化治疗的范式转变?

From sequential to combination and personalised therapy in lupus nephritis: moving towards a paradigm shift?
PubMed 文献 · Ann Rheum Dis · 2021-09-14

该观点文章讨论狼疮性肾炎当前序贯治疗模式下完全肾脏缓解率仅20-30%、10年内5-20%进展至终末期肾病的困境,并评述voclosporin与belimumab作为标准治疗附加药物的利弊,以及obinutuzumab和anifrolumab在III期试验中的前景,指出联合方案正挑战序贯概念,治疗选择需依托生物标志物与组织层面炎症表型分析。

要点

  • 序贯治疗下6-12个月完全肾脏缓解率仅20-30%,10年内5-20%进展至终末期肾病。
  • voclosporin与belimumab是近期III期试验成功后首批获批用于狼疮性肾炎的附加药物。
  • 联合方案挑战序贯概念,治疗选择需生物标志物与组织炎症表型映射支持。

核心结论

  • 狼疮性肾炎治疗格局正在改变,联合治疗方案挑战传统序贯概念。
  • 治疗手段丰富后核心挑战转为如何为合适患者选择合适治疗。
  • 需通过生物标志物调查与组织层面炎症表型映射实现个体化治疗。

研究设计与样本

  • 本文为观点文章,讨论狼疮性肾炎序贯治疗范式及联合与个体化治疗前景。

主要发现

  • 序贯治疗下6-12个月内完全肾脏缓解率仅20-30%。
  • 10年内5-20%的狼疮性肾炎患者进展至终末期肾病。
  • voclosporin与belimumab作为标准治疗附加药物在近期随机III期试验中成功并获批。
  • obinutuzumab与anifrolumab在初步有利信号后正在III期试验中测试。

关键数值与推荐

  • 完全肾脏缓解率在6-12个月内为20-30%。
  • 10年内终末期肾病发生率为5-20%。
  • 治疗目标确定依据临床、组织病理学或免疫病理学特征尚不确定。
  • 在可靠无创生物标志物出现前,组织学评估仍是金标准,需重复肾活检指导治疗评估与决策。

临床怎么用

  • 当前序贯治疗下完全肾脏缓解率有限,需关注联合治疗策略。
  • voclosporin与belimumab可作为标准治疗的附加药物。
  • 治疗决策可依据重复肾活检的组织学评估,直至可靠无创生物标志物可用。
  • 未来需通过生物标志物与组织炎症表型映射实现个体化治疗选择。

局限性

  • 本文为观点文章,未报告原始研究数据。
  • 治疗目标基于临床、组织病理学或免疫病理学特征尚不确定。
  • 可靠无创生物标志物缺乏,组织学评估需重复肾活检。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The current treatment paradigm in lupus nephritis consists of an initial phase aimed at inducing remission and a subsequent remission maintenance phase. With this so-called sequential treatment approach, complete renal response is achieved in a disappointing proportion of 20-30% of the patients within 6-12 months, and 5-20% develop end-stage kidney disease within 10 years. Treat-to-target approaches are detained owing to uncertainty as to whether the target should be determined based on clinical, histopathological, or immunopathological features. Until reliable non-invasive biomarkers exist, tissue-based evaluation remains the gold standard, necessitating repeat kidney biopsies for treatment evaluation and therapeutic decision-making. In this viewpoint, we discuss the pros and cons of voclosporin and belimumab as add-on agents to standard therapy, the first drugs to be licenced for lupus nephritis after recent successful randomised phase III clinical trials. We also discuss the prospect of obinutuzumab and anifrolumab, also on top of standard immunosuppression, currently tested in phase III trials after initial auspicious signals. Undoubtably, the treatment landscape in lupus nephritis is changing, with combination treatment regimens challenging the sequential concept. Meanwhile, the enrichment of the treatment armamentarium shifts the need from lack of therapies to the challenge of how to select the right treatment for the right patient. This has to be addressed in biomarker surveys along with tissue-level mapping of inflammatory phenotypes, which will ultimately lead to person-centred therapeutic approaches. After many years of trial failures, we may now anticipate a heartening future for patients with lupus nephritis.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Parodis I, Houssiau FA. From sequential to combination and personalised therapy in lupus nephritis: moving towards a paradigm shift? Ann Rheum Dis. 2021. PMID: 34521616. doi:10.1136/annrheumdis-2021-221270

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。